Production of chicken monoclonal antibody

Nishinaka, Shigeyuki; Asaoka, Hideyuki; Suzuki, Takashi; Matsuda, Haruo

doi:10.1007/978-94-011-2844-5_71

Cited by 2 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The new cell line was efficient in the development of antibody-producing hybridomas with highly reactive IgG secretion ability of 6 months. These cell lines were further improved and several chicken hybridomas were successfully developed [29,78]. However, chicken hybridoma technology has been explored in limits and most of the investigators prefer to use phage display method over hybridoma for the development of chicken mAbs [79].…”

Section: Chickenmentioning

confidence: 99%

Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives

Parray

Shukla

Samal

et al. 2020

International Immunopharmacology

142

125

View full text Add to dashboard Cite

The advancements in technology and manufacturing processes have allowed the development of new derivatives, biosimilar or advanced improved versions for approved antibodies each year for treatment regimen. There are more than 700 antibody-based molecules that are in different stages of phase I/II/ III clinical trials targeting new unique targets. To date, approximately more than 80 monoclonal antibodies (mAbs) have been approved. A total of 7 novel antibody therapeutics had been granted the first approval either in the United States or European Union in the year 2019, representing approximately 20% of the total number of approved drugs. Most of these licenced mAbs or their derivatives are either of hybridoma origin or their improvised engineered versions. Even with the recent development of high throughput mAb generation technologies, hybridoma is the most favoured method due to its indigenous nature to preserve natural cognate antibody pairing information and preserves innate functions of immune cells. The recent advent of antibody engineering technology has superseded the species level barriers and has shown success in isolation of hybridoma across phylogenetically distinct species. This has led to the isolation of monoclonal antibodies against human targets that are conserved and non-immunogenic in the rodent. In this review, we have discussed in detail about hybridoma technology, its expansion towards different animal species, the importance of antibodies isolated from different animal sources that are useful in biological applications, advantages, and limitations. This review also summarizes the challenges and recent progress associated with hybridoma development, and how it has been overcome in these years to provide new insights for the isolation of mAbs.

show abstract

Section: Chickenmentioning

confidence: 99%

Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives

Parray

Shukla

Samal

et al. 2020

International Immunopharmacology

142

125

View full text Add to dashboard Cite

show abstract

“…pAbs generally show large batch-to-batch differences and nonspecific binding, while mAbs, with the advantages of high reproducibility and specificity, are indispensable to the development of reliable immunoassays . Initial attempts to produce chicken mAbs by hybridoma technology exhibited limited success because the neoplastic B cells used in the fusion process were unstable/inappropriate, and the formed hybridomas could not secrete antibodies during cell culture. , Subsequently, some chicken mAbs were produced successively by replacing different myeloma cells to improve antibody secretion ability of formed hybridomas. − Despite this, chicken hybridoma technology has not been extensively explored because of limited available myeloma cells and low fusion efficiency compared with mouse hybridoma from well-established myeloma sp2/0. To the best of our knowledge, no studies have applied IgY mAbs producing by hybridoma technology in the food samples.…”

Section: Advances In the Production Of Chicken Igymentioning

confidence: 99%

Advances in Chicken IgY-Based Immunoassays for the Detection of Chemical and Biological Hazards in Food Samples

Dou

Zhang

Bai

et al. 2022

J. Agric. Food Chem.

View full text Add to dashboard Cite

As antibodies are the main biological binder for hazards in food samples, their performance directly determines the sensitivity, specificity, and reproducibility of the developed immunoassay. The overwhelmingly used mammalian-derived antibodies usually suffer from complicated preparation, high cost, frequent bleeding of animals, and sometimes low titer and affinity. Chicken yolk antibody (IgY) has recently attracted considerable attention in the bioanalytical field owing to its advantages in productivity, animal welfare, comparable affinity, and high specificity. However, a broad understanding of the application of IgY-based immunoassay for the detection of chemical and biological hazards in food samples remains limited. Here, we briefly summarized the diversity, structure, and production of IgY including polyclonal and monoclonal formats. Then, a comprehensive overview of the principles, designs, and applications of IgY-based immunoassays for these hazards was reviewed and discussed, including food-borne pathogens, food allergens, veterinary drugs, pesticides, toxins, endocrine disrupting chemicals, etc. Thus, the trend of IgY-based immunoassays is expected, and more IgY types, higher sensitivity, and diversification of recognition-to-signal manners are necessary in the future.

show abstract

Production of chicken monoclonal antibody

Cited by 2 publications

References 7 publications

Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives

Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives

Advances in Chicken IgY-Based Immunoassays for the Detection of Chemical and Biological Hazards in Food Samples

Contact Info

Product

Resources

About